New data backs Transgene's lung cancer vaccine

LONDON, Sept 15 (Reuters) - French biotech company Transgene (TRNG.PA) said on Monday that further clinical results showed the survival benefits of its therapeutic vaccine TG4010 in treating patients with advanced non-small cell lung cancer.

Results of a Phase IIb trial involving 148 patients demonstrated 39 percent of patients on TG4010 and chemotherapy were alive at 17 months compared to 23 percent on chemotherapy alone.

The results were presented at the annual meeting of the European Society of Medical Oncology in Stockholm.

Philippe Archinard, Transgene's CEO, said the results were "extremely promising" and he confirmed the company was seeking a collaborative partnership for the product.

Nomura Code Securities analyst Chris Redhead said the data should help Transgene in partnership talks. (Reporting by Ben Hirschler; editing by Rory Channing)